Trump’s march-in rights threat: Why pharma is rethinking collaborations

Federal oversight, funding cuts, and patent uncertainties are forcing universities, startups, and pharma companies to reassess partnership models, finds Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Harvard’s patent portfolio at risk as Trump turns up the pressure

11 August 2025 Administration targets university’s federally funded research | Commerce Secretary warns of patent seizure under Bayh-Dole Act | Harvard given deadline to provide list of federally funded patents | Uncertainty continues across universities amid broader research cuts.

Americas

President Trump 2.0: Five major areas to watch

7 November 2024 As Donald Trump celebrates a second term, LSIPR looks at how key IP areas could be affected ahead of his return to the Oval Office.

Generics

‘March-in’ rights: Why Biden’s changes contradict the point of Bayh-Dole

18 February 2024 While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.